<?xml version="1.0" encoding="UTF-8"?>
<p id="Par62">However, there is a dire need for development and evaluation of specific antivirals against COVID-19. There have been attempts to explore the applicability of already existing antivirals, potential antivirals, or a combination thereof along with supportive medicines; however, the focus should be on designing and adopting safe and effective modalities against SARS-CoV-2. These include developing neutralizing antibodies, oligonucleotides targeting SARS-CoV-2 RNA genome, passive antibody transfer, drug repurposing using available antivirals, anti-viral proteases, blocking coronavirus receptors like ACE2, targeting spike proteins, and combination therapies [
 <xref ref-type="bibr" rid="CR247">247</xref>â€“
 <xref ref-type="bibr" rid="CR253">253</xref>].
</p>
